Clinical course and immune response of a renal cell carcinoma patient to adoptive transfer of autologous cytotoxic T lymphocytes

Clinical and Experimental Immunology

Volumn 134, Issue 2, 2003, Pages 264-269

  Kawai, K ^a   Saijo, K ^b   Oikawa, T ^a,b   Morishita, Y ^a   Noguchi, M ^a   Ohno, T ^b   Akaza, H ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

Author keywords

Adoptive immunotherapy; Cytotoxic T lymphocyte; Eosinophilia

Indexed keywords

ALPHA INTERFERON; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CIMETIDINE; HLA ANTIGEN; MONOCLONAL ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DISEASE COURSE; EOSINOPHILIA; FLOW CYTOMETRY; HLA TYPING; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MALE; NEPHRECTOMY; PRIORITY JOURNAL;

CARCINOMA, RENAL CELL; CYTOTOXICITY, IMMUNOLOGIC; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KIDNEY NEOPLASMS; MIDDLE AGED; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0242521303     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02278.x     Document Type: Article

References (28)

1. Kawakami Y, Eliyahu S, Delgado CH et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994; 91:6458-62.
2. Rosenberg SA. Progress in human tumor immunology and immunotherapy. Nature 2001; 411:380-4.
3. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2. Identification of the antigens mediating response. Ann Surg 1998; 228:307-19.
4. Rosenberg SA, Packard BS, Aebersold PM et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988; 319:1676-80.
5. Gaugler B, Brouwenstijn N, Vantomme V et al. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal cell carcinoma. Immunogenetics 1996; 44:323-30.
6. Brandle D, Brasseur F, Weynants P, Boon T, Van den Eynde BJ. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med 1996; 183:2501-8.
7. Neumann E, Engelesberg A, Decker J et al. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res 1998; 58:4090-5.
8. Liu SQ, Saijo K, Todoroki K, Ohno T. Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumor sections. Nature Med 1995; 1:267-71.
9. Liu SQ, Shiraiwa H, Kawai K et al. Tumor-specific autologous cytotoxic T lymphocytes from tissue sections. Nature Med 1996; 2:1283.
10. Liu SQ, Kawai K, Shiraiwa H et al. High rate of induction of human autologous cytotoxic T lymphocytes against renal cell carcinoma cells cultured with an interleukin cocktail. Jpn J Cancer Res 1998; 89:1195-201.
11. Tsurushima H, Liu SQ, Tuboi K et al. Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes. Jpn J Cancer Res 1999; 90:536-45.
12. Kawai K, Sasaki T, Saijou K, Akaza H, Koiso K, Ohno T. Additive effects of antitumor drugs and lymphokine-activated killer cell cytotoxic activity in tumor cell killing determined by lactate-dehydrogenase-release assay. Cancer Immunol Immunother 1992; 35:225-9.
13. Saotome K, Morita H, Umeda M. Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs. Toxicol In Vitro 1989; 3:317-21.
14. Chang A, Aruga A, Cameron MJ et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 1997; 15:796-807.
15. Plautz GE, Barnett GH, Minner DW et al. Systemic T cell adoptive immnunotherapy of malignant gliomas. J Neurosurg 1998; 89:42-51.
16. Figlin RA, Thompson JA, Bukowski RM et al. Muticenter, randomized, phase III trial of CD8+ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999; 17:2521-9.
17. Yee C, Riddell SR, Greenberg PD. Prospects for adoptive T cell therapy. Curr Opin Immunol 1997; 9:702-8.
18. Rivoltini L, Viggiano V, Spinazze S et al. In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5. Int J Cancer 1993; 54:8-15.
19. + T cells in the antitumor immune response. J Exp Med 1998; 188:2357-68.
20. De Groen PC, Kephart GM, Gleich GJ, Ledwig J. The eosinophil as an effector cell of the immune response during hepatic allograft rejection. Hepatology 1994; 20:654-9.
21. Soiffer R, Lynch T, Mihm M et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998; 95:13141-6.
22. Logan TF, Banner B, Rao U et al. Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy. Clin Exp Immunol 1998; 114:347-54.
23. Kawai K, Tani K, Yamashita N et al. Clinical course of an advanced renal cell carcinoma patient treated with GM-CSF gene therapy (GVAX): the first experience of cancer gene therapy in Japan. Int J Urol 2002; 9:462-6.
24. Genevee C, Diu A, Caignard A et al. An experimentally validated panel of subfamiliy-specific oligonecleotide primers (Va1-w29/Vb1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur J Immunol 1992; 22:1261-9.
25. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74:181-273.
26. Sommer M, Schmidt R, Lambrecht E, Fink H, Geiger H, Lenz T. Rapidly progressive glomerulonephritis in a patient with advanced renal cell carcinoma. Nephrol Dial Transplant 1998; 13:2107-9.
27. Ahumed M, Solangi K, Abbi R, Adler S. Nephrotic syndrome, renal failure, and renal malignancy: an unusual tumor-associated glomerulonephritis. J Am Soc Nephrol 1997; 8:848-52.
28. Beaufils H, Patte R, Aubert P et al. Renal immunopathology in renal cell carcinoma. Virchows Arch A Pathol Anat Histopathol 1984; 404:87-97.